Analysts Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $4.25

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $4.25.

A number of equities research analysts have recently weighed in on INO shares. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Wall Street Zen downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, June 21st. Weiss Ratings raised Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Finally, HC Wainwright cut their price target on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research note on Monday, June 1st.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock opened at $1.10 on Wednesday. The stock has a 50-day moving average price of $1.20 and a 200 day moving average price of $1.51. The company has a market cap of $90.50 million, a P/E ratio of -0.76 and a beta of 1.49. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. On average, equities analysts forecast that Inovio Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in INO. Focus Partners Wealth purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth about $33,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Inovio Pharmaceuticals by 752.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 18,160 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Inovio Pharmaceuticals by 4,396.0% during the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 16,309 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter valued at about $41,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.